San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor during the weight loss drug current market in February after revealing promising facts from a mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection and in March the com